Free Trial
NASDAQ:BCAX

Bicara Therapeutics Q4 2024 Earnings Report

Bicara Therapeutics logo
$14.50 -0.21 (-1.43%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$14.54 +0.04 (+0.24%)
As of 05/2/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bicara Therapeutics EPS Results

Actual EPS
-$0.39
Consensus EPS
-$0.31
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

Bicara Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bicara Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 27, 2025
Conference Call Time
7:30AM ET

Upcoming Earnings

Bicara Therapeutics' Q1 2025 earnings is scheduled for Thursday, June 26, 2025

Bicara Therapeutics Earnings Headlines

Wedbush Lifts Earnings Estimates for Bicara Therapeutics
Watch This Robotics Demo Before July 23rd
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
See More Bicara Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bicara Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bicara Therapeutics and other key companies, straight to your email.

About Bicara Therapeutics

Bicara Therapeutics (NASDAQ:BCAX), a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

View Bicara Therapeutics Profile

More Earnings Resources from MarketBeat